Addressing disparities in HRRm testing access
Episode 7. Alicia Morgans and Neal Shore explore persistent disparities in HRRm testing access for mPC and the strategies needed to close them. They examine where disparities are most visible, across geography, race, and specialty, and how timing and urgency complicate workflows. Shore advocates for universal germline testing and highlights the role of guidelines, telemedicine, and cascade family testing in improving equity. The discussion also tackles cultural skepticism, systemic barriers, and global knowledge gaps, underscoring why education and inclusive data are critical for advancing precision care in mPC. View transcript.
Chapters
01:06 Key areas of disparity in HRR testing
06:54 Balancing urgency and HRR testing access
10:31 Overcoming barriers to HRR testing
14:00 Tackling mistrust in HRR genetic testing
18:10 HRR testing: Disparities and gaps
Meet the guest speaker
Neal Shore, MD, FACS
Neal Shore serves as the Medical Director for the Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA. Shore is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and the co-chair of the annual American Urological Association (AUA) International Prostate Forum.
Disclosures: Honoraria and/or fees from AbbVie, Alessa Therapeutics, Alkido Pharma, Amgen, Arquer Diagnostics, Asieris Pharmaceuticals, Astellas, AstraZeneca, Bayer, Boston Scientific, Bristol Myers Squibb, Clarity Pharma, Clovis Oncology, Cold Genesys, Dendreon, Exact Images, Exact Sciences, FerGene, Ferring, Foundation Medicine, GC Oncology, Genentech, GenesisCare, Guardant Health, ImmunityBio, Incyte, Invitae, Janssen, Lantheus, Lilly, Mdxhealth, Merck, Minomic, Myovant Sciences, Myriad, NGM Bio, Nonagen Bioscience, Novartis, Novartis (Advanced Accelerator Applications), Nymox Pharmaceutical Corporation, Pacific Edge, Pfizer, Photocure, PlatformQ, Profound Pharma, Promaxo, Propella Therapeutics, Protara Therapeutics, Sanofi, Sesen Bio, Speciality Networks, Telix, Tolmar, UroGen Pharma, Vaxiion Therapeutics, and Vessi Medical.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.